Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from BioHarvest Sciences ( (BHST) ).
BioHarvest Sciences announced a Virtual Investor Webinar scheduled for September 10, 2025, where CEO Ilan Sobel will provide updates on the company’s new initiatives and ‘Big Bets’ for the second half of 2025. The webinar will cover developments in both consumer and CDMO business units, focusing on the Health Pros program, a new hydration product, and key CDMO efforts. These initiatives aim to expand product offerings and the CDMO pipeline, driving profitable growth and long-term shareholder value.
The most recent analyst rating on (BHST) stock is a Hold with a $9.50 price target. To see the full list of analyst forecasts on BioHarvest Sciences stock, see the BHST Stock Forecast page.
Spark’s Take on BHST Stock
According to Spark, TipRanks’ AI Analyst, BHST is a Neutral.
The overall stock score is primarily influenced by the company’s financial challenges, including negative equity and profitability issues. However, positive technical indicators and promising earnings call guidance provide some optimism. The valuation remains a concern due to negative earnings and lack of dividends.
To see Spark’s full report on BHST stock, click here.
More about BioHarvest Sciences
BioHarvest Sciences Inc. is a leader in Botanical Synthesis, utilizing its patented technology to produce active plant ingredients without cultivating the actual plant. The company operates in two major business areas: as a contract development and production organization (CDMO) for customers needing complex molecules, and as a creator of proprietary nutraceutical health and wellness products, including dietary supplements.
Average Trading Volume: 13,123
Technical Sentiment Signal: Buy
Current Market Cap: $141.8M
For detailed information about BHST stock, go to TipRanks’ Stock Analysis page.